- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Squamous cell carcinoma (SCC)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1548KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 447KB)
Cemiplimab – November 2020
Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
Last updated
19 March 2021